English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12190/12972 (94%)
造访人次 : 1061413      在线人数 : 881
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧:
  • 您可在西文检索词汇前后加上"双引号",以获取较精准的检索结果
  • 若欲以作者姓名搜寻,建议至进阶搜寻限定作者字段,可获得较完整数据
  • 进阶搜寻
    主页登入上传说明关于NHRI管理 到手机版

    类别浏览

    正在载入社群分类, 请稍候....

    年代浏览

    正在载入年代分类, 请稍候....

    "Rokutanda, N"的相关文件  

    回到依作者浏览

    显示 7 项.

    类别 日期 题名 關聯 档案
    [陳立宗] 會議論文/會議摘要 2019-10 A phase III, randomized, double-blind, placebo-controlled, international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary tract cancers: TOPAZ-1 -
    [陳立宗] 會議論文/會議摘要 2022-02-01 A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1 -
    [陳立宗] 會議論文/會議摘要 2022-09 Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC) -
    [陳立宗] 會議論文/會議摘要 2022-11 Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC) -
    [陳立宗] 期刊論文 2023-07 Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC) [Erratum:Annals of Oncology. 2022 Nov;33(Suppl. 9):S1462 -
    [陳立宗] 期刊論文 2023-11 Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer -
    [陳立宗] 期刊論文 2024-08 Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): Updated overall survival from a randomised phase 3 study -

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈